Learning from Iressa – when and how to develop companion diagnostics
This article was originally published in Clinica
Executive Summary
Datamonitor healthcare analyst James Wade looks back over the path to market taken by one of AstraZeneca's oncology drugs and outlines some key lessons for pharmaceutical companies developing personalised cancer therapies